Literature DB >> 3865653

Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma.

F Wingen, D Schmähl.   

Abstract

The distribution of 14C-APD and 99mTc-APD (APD = 3-amino-1-hydroxypropane-1,1-diphosphonic acid) in untreated rats and in rats bearing intratibially transplanted osteosarcomas was investigated autoradiographically and scintigraphically. Also investigated was the effect of high doses of APD on survival time and tumor growth of osteosarcoma-bearing rats. Intravenous administration of APD resulted in high rates of APD accumulation in bones, tumor tissue and pulmonary metastases as well as in dose-related accumulation in the liver. No significant increase in the median survival time of tumor-bearing animals was achieved at the two dosage schemes tested, i.e. 2 X 23.5 mg/kg and 10 X 11.75 mg/kg APD. The growth of primary tumors was slightly increased by administration of APD. The chemosensitivity of the transplantable osteosarcoma model was demonstrated by comparison with dacarbazine-treated control animals.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3865653

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  8 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  In vivo and in vitro investigations on biological effects of aromatic bis-(2-chloroethyl)amino-bisphosphonic acids, new agents proposed for chemotherapy of bone tumors: cytostatic activity in rat osteosarcoma; toxicity and genotoxicity in liver and bone marrow; mutagenicity in S. typhimurium.

Authors:  B L Pool; M Berger; J R Schlehofer; F Wingen
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

3.  Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agents.

Authors:  F Wingen; B L Pool; P Klein; T Klenner; D Schmähl
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

4.  Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?

Authors:  T Klenner; F Wingen; B K Keppler; B Krempien; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

Review 5.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.

Authors:  F Wingen; H Sterz; H Blum; H Möller; W Pittermann; B L Pool; H J Sinn; H Spring; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

7.  Changing metastatic patterns of a transplantable rat osteosarcoma.

Authors:  F Wingen; E Weber
Journal:  Clin Exp Metastasis       Date:  1987 Jan-Mar       Impact factor: 5.150

8.  Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.

Authors:  F Wingen; T Eichmann; C Manegold; B Krempien
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.